4-[5-[(rac)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine for use in the prevention and / or treatment of fatigue in mammals

JP7579337B2Active Publication Date: 2024-11-07スーリンクラース
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2022523459
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-11-05
Filing Date
2020-10-16
Publication Date
2024-11-07
Estimated Expiration
2040-10-16

AI Technical Summary

Benefits of technology

【0044】 CG Abdallah,et al.,Chronic Stress(Thousand Oaks).2017 Feb;1を参照すると、痛みに作用する物質をストレスの指標に用いることができると仮定する理由はない。さらに、疼痛治療に使用するためのTT001の効果は示されていない。TT001は、うつ病及び不安症の治療に有効ではないことが示されている。しかしながら、新たな結果は、ストレス/過労の治療における物質の予想外の効果を示す。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579337000001
    Figure 0007579337000001
  • Figure 0007579337000002
    Figure 0007579337000002
  • Figure 0007579337000003
    Figure 0007579337000003
Patent Text Reader

Abstract

The present invention relates to the compound 4-[5-[(rac)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4 triazol-3-yl]pyridine (TT00, TT001 and / or TT002), or a pharmaceutical composition comprising said TT00, TT001 and / or TT002, for use in the prevention and / or treatment of fatigue, optionally in combination with one or more disorders selected from surgical gastroesophageal reflux, anxiety, ulcers, renal and vascular disorders, wound healing and / or anorexia, in a mammal, such as a dog, pig, cat or horse.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the compound 4-[5-[(rac)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine (TT00, TT001 and / or TT002) or a pharmaceutical composition comprising said TT00, TT001 and / or TT002, for use in the prevention and / or treatment of fatigue, optionally in combination with one or more disorders selected from surgical gastroesophageal reflux, anxiety, ulcers, renal and vascular disorders, wound healing and / or anorexia, in a mammal, such as a dog, pig, cat or horse. [Background technology]

[0002] Induction of anesthesia in mammals encompasses challenges on many levels. Common stress experiences by mammals such as cats, pigs, dogs and horses can lead to the use of high concentrations of pharmaceuticals necessary to induce and maintain anesthesia.

[0003] During the recovery period, the patient again experiences discomfort, pain and stress. These conditions prolong the recovery and inactivity period. The longer the patient is in recovery, the higher the risk of vascular and renal events and the reduced wound healing. It can also affect appetite, resulting in anorexia.

[0004] Commonly used in surgery today are anxiolytics and analgesics to deal with pre- and post-operative stress and pain. Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used. Typical side effects of NSAIDs in dogs are vomiting, anorexia, depression and diarrhea. Other serious side effects include gastrointestinal ulcers, liver / kidney failure and even death have been reported.

[0005] CG Abdallah,et al.,Chronic Stress(Thousand Oaks).2017 Feb;1.doi:10.1177 / 2470547017704763.Epub 2017 Jun 8 describes the difference between pain disorders and stress, stating that the definition of stress is very broad. For example, exposure to intense pictures and acute aversive stimuli-like acute pain are both stressful, but may involve different physiological functions. Furthermore, cortisol release and hippocampal activation are often observed after stress, but are rarely seen after acute pain. Substances that may be effective against pain may not be very effective against stress.

[0006] Christian LM et al., Stress and Wound Healing, Neuroimmunomodulation. 2006; 13(5-6): 337-346, doi.org / 10.1159 / 000104862 discloses that it has been found that stress can significantly delay wound healing. Stressors ranging in magnitude and duration impair healing in humans and animals. For example, in humans, the chronic stress of caregiving and the relatively short stress of academic examinations impede healing. Similarly, restraint stress delays healing in mice. The effects of stress on wound healing and surgical recovery can be exacerbated by the effects of physical pain, which is a common symptom of both laboratory wounds and surgery.

[0007] GB Glavin et al., The neurobiology of stress ulcers, Brain Research Reviews, 16 (1991) 301-343, 1991 Elsevier Science Publishers BV, doi.org / 10.1016 / 0165-0173 (91) 90012-W discloses that acute gastric lesions occur in both animals and humans after exposure to a variety of stressors, including some that are difficult to quantify. In 1936, Selye published two short papers reporting the occurrence of certain physiological changes in response to a wide variety of stressors. These responses included adrenal hypertrophy, thymic lymphoid involution, and acute ulcers in the stomach. These were to become classic symptoms of the stress syndrome. At that time, Selye reported that immobilization of laboratory rats caused this syndrome. Thus, in 1936, a link was made between stress and gastric ulcer formation, as shown in Figure 1 of the paper. However, it would be another 20 years before further important publications in the field appeared. Mice subjected to restraint stress also had significantly higher levels of serum corticosterone compared to unstressed controls. When stressed animals were treated with a glucocorticoid receptor antagonist (RU40555), their healing rates were comparable to those of unstressed animals, so the increase in serum corticosterone was found to be important for the delayed healing and increased incidence of infection. These results demonstrated that the inhibitory effect of glucocorticoids on inflammatory activity at the wound site is a key factor linking stress and healing.

[0008] Lloyd JKF,et al.,Minimising Stress for Patients in the Veterinary Hospital,Veterinary Sciences,13 Apr 2017,4(2)DOI:10.3390 / vetsci4020022 discloses that factors that exacerbate fear and induce aggression in dogs also apply to cats. Dogs and cats can become extremely stressed by being caged away from their owners. These animals undergo physiological changes such as increased heart rate and release of cortisol, both of which can be associated with negative emotions such as fear and anxiety. Additionally, stressed animals may not eat or drink enough, which can slow recovery.

[0009] Balcome at al., Contemporary Topics 2004 by the American Association for Laboratory Animal Science. Vol 43. No. 6 / November 2004, discloses that laboratory routines are associated with stress and that animals do not easily become accustomed to them. Data suggest that significant fear, stress, and possibly distress are predictable consequences of routine laboratory procedures, and that these phenomena have substantial scientific and humane implications for the use of animals in laboratory research.

[0010] Immobilization alone or in combination with other factors, most commonly cold room temperature, has been used extensively to study pharmacological agents as modulators of gastric ulcers in the search for treatment strategies. The most common procedures currently used are supine restraint in a cold (4°C) room or tube restraint + partial immersion in room temperature (20°C) water. These techniques are chosen because they produce relatively large amounts of ulceration (linear erosions averaging 15-40 mm are common) that can be modified by numerous treatments both before and after stress ulcer-inducing techniques such as stress preloading or bed rest after the ulcer-forming stressor.

[0011] Nagy et al., Forced swimming test in mice: A review of antidepressant activity, February 2005, Psychopharmacology 177(3):245-55, reported that "forced swimming" in room temperature water (23°C) for 5 hours also produced hemorrhagic gastric gland lesions.

[0012] Saeid Golbidi,et al.,Am J Physiol Heart Circ Physiol 308:H 1476-H1498,2015.Review First published April 17,2015 discloses how chronic stress affects the cardiovascular system. The proatherosclerotic effects of forced swimming have been shown in a stress protocol consisting of restraint and forced swimming in rats fed a normal diet. This chronic stress model enhanced various aspects of atherosclerosis, including increased cholesterol and triglyceride blood levels, decreased HDL, increased oxidative stress, decreased vascular elastic fibers, and enhanced foam cell formation. The hypercholesterolemic and oxidative effects of stress remained 20 weeks after cessation of the stress protocol. The detrimental effects of forced swimming on cardiac function have also been shown in this experimental setting.

[0013] Marchon RG,et al.,Kidney Blood Press Res 2018;43:1919-1926,2018 The Author(s)Published by S.Karger AG,Basel,doi.org / 10.1159 / 000496004 discloses the immediate and late effects of stress on the kidneys of immature and adult rats. The results show that, when assessed immediately, stressed immature animals showed reduced kidney weight and volume as well as an increased cortex-medulla ratio compared to the control group. Furthermore, stressed immature and adult animals assessed immediately had reduced glomerular volume density. Most importantly, all stressed groups showed a reduced number of glomeruli per kidney. Other analyzed parameters were not significantly different. It is concluded that chronic stress induced around maturity led to irreversible glomerular loss, whereas removal of the stress stimulus interrupted renal dysfunction.

[0014] Recently, complications due to reflux in the surgical environment of companion animals have been noted in "Prevalence of and risk factors for intraoperative gastroesophageal reflux and postanaesthetic vomiting and diarrhoea in dogs undergoing general anaesthesia, Journal of Veterinary Emergency and Critical Care 27(4)2017,pp397-408 doi:10.1111 / vec.12613". The authors conclude that there is a high prevalence of reflux in anesthetized dogs. This also applies to cats "Prevalence of Gastroesophageal Reflux in Cats During Anaesthesia and Effect of Omeprazole on Gastric pH, J Vet Intern Med 2017;31:734-742".

[0015] The realization that reflux is a common ailment in mammalian surgery / surgery has opened a new field of investigational drugs. Rodriguez-Alarcon, CA et al. "Gastroesophageal reflux in anesthetized dogs: a review" In: Rev Colomb Cienc Pecu, 2015, Vol. 28, pp. 144-155 discloses the use of active ingredients such as ranitidine to reduce postoperative cases of gastroesophageal reflux (GER). Ranitidine reduces acid production, which only lowers the pH in the stomach; ranitidine has no effect on reflux itself.

[0016] Reflux can lead to peptic ulcers and other complications that can affect the recovery time of a mammal or patient after surgery.

[0017] Although rodent animal models can predict effects in humans, no studies have been presented that show that rodent models predict outcomes in dogs, and at the same time, there are few larger animal models in which these effects can be measured.

[0018] Comparison of species metabolites Before a molecule can become a drug candidate, many things must be cleared. Two important steps that a molecule must go through are species suitability through metabolite profile evaluation.

[0019] In the preclinical part of drug development, studies are designed to determine the metabolite profile and characterize selected metabolites produced after incubation of the molecule in rat and human hepatocytes. The results obtained are used to compare human hepatic metabolism with the rodent models used in safety studies.

[0020] One method used is to harvest rat and human hepatocytes and incubate them with the molecule. The metabolite profile in the supernatant is recorded by liquid chromatography. Selected metabolites are characterized by accurate mass spectrometry. There may be more than 10 different metabolites from hepatic metabolism.

[0021] The metabolite profile should be similar between the two species. If this is not the case, the predictability of the rodent model to humans is not evident and the molecule will likely not be a drug candidate.

[0022] It is also well known that for certain indications, such as inflammatory diseases, the predictability of rodent models relative to humans is very low (PNAS|February 26, 2013|vol.110|no.9|3507-3512, Genomic responses in mouse models poorly mimic human inflammatory diseases).

[0023] This also applies to clinical pain. Unfortunately, rodent biology often fails to accurately predict the biology and pharmacology of clinical pain states in humans (Blackburn-Munro 2004; Le Bars et al. 2001, Translational Pain Research: From Mouse to Man. Kruger L, Light AR, editors. Boca Raton, FL: CRC Press / Taylor&Francis; 2010. Chapter 17 Large Animal Models for Pain Therapeutic Development, Darrell A. Henze and Mark O. Urban).

[0024] Based on rodent models, and the difficulty of predicting both drug metabolism and metabolite profiles between species, as well as responses in humans, one of skill in the art cannot predict the efficacy and toxicity of a drug for one species based on data from another species, unless specific studies are performed to validate the activity of the compound.

[0025] Examples of drugs with different effects in different species Tramadol is widely used as an analgesic with good efficacy in humans, but has no efficacy in dogs. (J Am Vet Med Assoc.2018 Feb 15;252(4):427-432.doi:10.2460 / javma.252.4.427.,Lack of effectiveness of tramadol hydrochloride for the treatment of pain and joint dysfunction in dogs with chronic osteoarthritis.,Budsberg SC,Torres BT,Kleine SA,Sandberg GS,Berjeski AK.)

[0026] Tramadol is also known to have adverse effects, such as making dogs lose consciousness and balance, giving the impression of being "high". There are also drugs used in humans that are toxic to animals. Examples of this are phenolic drugs, including acetaminophen and aspirin, which should not be given to cats. (PLoS One.2011 Mar 28;6(3):e 18046.doi:10.1371 / journal.pone.0018046,Evolution of a major drug metabolizing enzyme defect in the domestic cat and other felidae:phylogenetic timing and role of hypercarnivory.Shrestha B1, Reed JM, Starks PT, Kaufman GE, Goldstone JV,Roelke ME,O'Brien SJ,Koepfli KP,Frank LG,Court MH,and Author information Comparative and Molecular Pharmacogenomics Laboratory,Department of Molecular Physiology and Pharmacology,Tufts University School of Medicine,Boston,Massachusetts,United States of America.Life Sci.2006 Nov 25;79(26):2463-73.Epub 2006 Oct 5).

[0027] The relatively large number of medications used during surgery makes optimizing recovery / convalescence periods more difficult.

[0028] Combination Drug Therapy (CDT) There are several studies looking at CDT for pain management.

[0029] Mao et al. J.Pain, 2011, vol12, pp157-166, disclose various combination drug therapies for the treatment of pain. Most of the treatments use opiates combined with another analgesic. mGluRs are not mentioned at all. Mao J.et al, reviews the available data on CDT in humans, but no mention of animals. In Table 1, the different combinations are listed and evaluated in terms of positive or negative results. It is also mentioned in Table 1 of Mao et al that the combination of tramadol and acetaminophen [oral] showed positive and better pain relief with add-on drugs in humans. If this CDT is given to cats, the toxicity can cause death in the cats.

[0030] Vet Rec.2019 Oct 5;185(13):406.doi:10.1136 / vr.105009.Epub 2019 Jul 18,Randomised trial of perioperative tramadol for canine sterilization pain management,and Meunier NV1,Panti A2,Mazeri S1,Fernandes KA3,Handel IG2,Bronsvoort BMC1,Gamble L3,Mellanby RJ2,Author information The Roslin Institute and Royal(Dick)School of Veterinary Studies,University of Edinburgh,Easter Bush,UK.Royal(Dick)School of Veterinary Studies,University of Edinburgh,Easter Bush,UK.Worldwide Veterinary Service,Cranborne,UK.Life Sci.2006 Nov 25;79(26):2463-73.Epub 2006 Oct 5.,cDNA cloning and characterization of feline CYP1A1 and CYP1A2.,Tanaka N1,Miyasho T,Shinkyo R,Sakaki T,Yokota H.,Author information Laboratory of Veterinary Biochemistry,Graduate School of Veterinary Medicine,Rakuno Gakuen See also University, Ebetsu, Hokkaido 069-8501, Japan.

[0031] There may be a common misconception that simply combining different drugs will have an additive effect. In Table 1 of Mao et al., one in four combinations does not produce a positive result. There are even situations in which combinations reduce the overall efficacy of the treatment.

[0032] It should be clear to the skilled person that clinical results in different species do not automatically translate to other species. Therefore, the skilled person should and will suggest an independent evaluation of efficacy and toxicity for each species. This is also clearly the position of the Medical Products Agency in most countries.

[0033] Thus, there is a challenge to reduce the time for post-operative recovery, particularly in mammals such as dogs, pigs, cats and horses.

[0034] TT00, or 4-[5-[(rac)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine [ka] , and TT001, or 4-[5-[(1R)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine, AZD2066, CAS number 934282-55-0; [ka] , and TT002, or 4-[5-[(1S)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine, [ka] has the molecular formula C 19 H 16 ClN5O2 and has a relative molecular weight of 381.8 (base).

[0035] TT00, and in particular TT001, are selective noncompetitive antagonists at the metabotropic glutamate receptor subtype 5 (mGluR5) that have been developed for the oral treatment of chronic pain syndromes of neuropathic origin, anxiety and gastroesophageal reflux disease (GERD) in humans.

[0036] TT00 affects the mGluR5 receptor in the central nervous system, which may result in central pain relief, reduced anxiety and reduced gastroesophageal reflux. Clinical development of TT001 was discontinued due to the substance's lack of efficacy in all indications.

[0037] During clinical development, dogs have been used for toxicity studies, but no efficacy studies have been performed for these indications. A bibliographic search does not reveal any publications on the shortening of recovery and treatment of anxiety and / or pain in dogs, pigs, cats or horses with the molecule.

[0038] WO 2007 / 040982 discloses the use of TT00, TT001 and / or TT002 in humans for the treatment of neurological, psychiatric or pain disorders. IC50 binding data at mGluR receptors and a study on the effect of TT00, TT001 or TT002 on TLESR in healthy dogs in relation to food intake are presented. No results of this study are disclosed. There is no clinical data at all, especially related to the treatment of pain after administration of TT00, TT001 and / or TT002.

[0039] Rohof, et al., Aliment. Pharmacol. Ther. 2012, vol 35, pp 1231-1242, disclose a clinical trial using TT001 to measure its effect on TLESR in healthy volunteers in relation to food ingestion. The results in Figures 2 and 4 show that only the high dose of 13 mg (approximately 0.19 mg / kg) has some effect 2-3 hours after food ingestion, but there was no significant effect on reflux either before food ingestion or 1-2 hours after food ingestion. Some serious side effects associated with the high dose of 13 mg are mentioned. No clinical data are disclosed in relation to pain treatment following administration of TT00, TT001 and / or TT002.

[0040] Furthermore, there are no published data on TT001 and hepatic metabolism and metabolite profiles in rats and dogs, and certainly not for rats compared to cats and horses.

[0041] Richard HP, The American Society for Pharmacology and Experimental Therapeutics JPET 315:711-721,2005 discloses the use of fenobam, a metabotropic glutamate (mGlu) 5 receptor antagonist, in anxiety in humans. The results show that fenobam significantly reversed stress-induced hyperthermia (SIH) in mice at doses of 10 (p<0.001) and 30 mg / kg (p<0.001). Studies conducted with TT001 in humans did not show any effect on anxiety in humans. Summary of the Invention [Problem to be solved by the invention]

[0042] There is an unmet need for the prevention and / or treatment of fatigue, optionally in combination with one or more disorders selected from surgical gastroesophageal reflux, anxiety, ulcers, renal and vascular disorders, wound healing and / or anorexia, in mammals such as dogs, pigs, cats or horses. There is a need for treatments with reduced side effects such as gastrointestinal and nephrotoxicity. [Means for solving the problem]

[0043] The present invention relates to the compounds 4-[5-[(rac)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine (TT00), 4-[5-[(1R)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine, (TT001) and / or 4-[5-[(1S)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine (TT002), or pharma- ceutically acceptable salts, solvates, isotopes, or mixtures thereof, for use in the prevention and / or treatment of fatigue in a mammal. In one aspect, the compound as defined above is for use in the prevention of fatigue in a mammal. One embodiment of the present invention will be described below, but the present invention is not limited thereto. [Invention A1] 2. The compound 4-[5-[(rac)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine (TT00), or 4-[5-[(1R)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine, (TT001) and / or 4-[5-[(1S)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine (TT002), or a pharma- ceutically acceptable salt, solvate, isotope, or mixture thereof, for use in the prophylaxis and / or treatment of fatigue in a mammal. [Invention A2] Compounds TT00, TT001 and / or TT002, or pharma- ceutically acceptable salts, solvates, isotopes or mixtures thereof, for use in a mammal under surgical conditions according to invention A1. [Invention A3] Compound TT00, TT001 and / or TT002, or a pharma- ceutically acceptable salt, solvate, isotope or mixture thereof, for use according to invention A1 or A2 in a mammal treated with one or more muscle relaxants. [Invention A4] Compounds TT00, TT001 and / or TT002, or pharma- ceutically acceptable salts, solvates, isotopes or mixtures thereof, for use according to invention A2 or A3, wherein said compounds are administered pre-operatively. [Invention A5] Compound TT00, TT001 and / or TT002, or a pharma- ceutically acceptable salt, solvate, isotope or mixture thereof, for use according to invention A2 or A3, wherein said compound is administered after said surgery. [Invention A6] Compound TT00, TT001 and / or TT002, or a pharma- ceutically acceptable salt, solvate, isotope or mixture thereof, for use according to any one of inventions A1 to A5, for use in dogs, cats, horses or pigs. [Invention A7] Compounds TT00, TT001 and / or TT002, or pharma- ceutically acceptable salts, solvates, isotopes or mixtures thereof, for use according to any one of inventions A1 to A6 in combination with the prophylaxis and / or treatment of ulcers, renal and / or vascular disorders. [Invention A8] Compound TT00, TT001 and / or TT002, or a pharma- ceutically acceptable salt, solvate, isotope or mixture thereof, for use according to any one of inventions A1 to A6 in combination with the prophylaxis and / or treatment of wound healing and / or anorexia. [Invention A9] Compounds TT00, TT001 and / or TT002, or pharma- ceutically acceptable salts, solvates, isotopes or mixtures thereof, for use according to any one of inventions A1 to A6 in combination with the prophylaxis and / or treatment of gastroesophageal reflux by surgery. [Invention A10] Compound TT00, TT001 and / or TT002, or a pharma- ceutically acceptable salt, solvate, isotope or mixture thereof, for use according to any one of inventions A1 to A6 in combination with anxiety. [Invention A11] Compounds TT00, TT001 and / or TT002, or pharma- ceutically acceptable salts, solvates, isotopes or mixtures thereof, for use according to any one of inventions A1 to A6 in combination with the prophylaxis and / or treatment of surgical gastroesophageal reflux and anxiety. [Invention A12] A pharmaceutical composition comprising compounds TT00, TT001 and / or TT002, or pharma- ceutically acceptable salts, solvates, isotopes or mixtures thereof, in combination with a pharma- ceutically acceptable adjuvant, diluent or carrier, for use in the prophylaxis and / or treatment of fatigue, optionally in combination with one or more disorders including gastroesophageal reflux due to surgery, anxiety, ulcers, renal and vascular disorders, wound healing and anorexia. [Invention A13] A pharmaceutical composition according to Invention A12 comprising (i) compound TT00, TT001 and / or TT002, or a pharma- ceutically acceptable salt, solvate or isotope thereof or a mixture thereof, (ii) a further therapeutic agent, or a pharma- ceutically acceptable salt or solvate thereof, and (iii) a pharma- ceutically acceptable excipient, carrier or diluent. [Invention A14] A pharmaceutical composition according to Invention A12 comprising (i) compound TT00, TT001 and / or TT002, or a pharma- ceutically acceptable salt, solvate or isotope thereof or a mixture thereof, and a pharma- ceutically acceptable excipient, carrier or diluent, (ii) a further therapeutic agent, or a pharma- ceutically acceptable salt or solvate thereof, and a pharma- ceutically acceptable excipient, carrier or diluent. [Invention A15] The pharmaceutical composition according to any one of Inventions A12 to A14, wherein said further therapeutic agent is an NSAID selected from the group comprising butylpyrrolidine, oxicams, propionic acid derivatives, fenamates, coxibs, and other non-steroidal anti-inflammatory drugs. [Invention A16] A pharmaceutical composition according to any one of Inventions A12 to A14, wherein the further therapeutic agent is an opiate selected from the group comprising tramadol or tapentadol. [Invention A17] A pharmaceutical composition according to any one of Inventions A12 to A14, wherein said further therapeutic agent is an antirheumatic drug. [Invention A18] Compounds TT00, TT001 and / or TT002 according to any one of Inventions A1 to A1, or pharma- ceutically acceptable salts, solvates, isotopes or mixtures thereof, or a pharmaceutical composition according to any one of Inventions A12 to A17, wherein compounds TT00, TT001 and / or TT002 are administered to a mammal at a dose of 0.1 to 5.0 mg / kg. [Invention A19] Compound TT00, TT001 and / or TT002 according to any one of Inventions A1 to A11, or a pharma- ceutically acceptable salt, solvate, isotope or mixture thereof, or a pharmaceutical composition according to any one of Inventions A12 to A17, wherein said compound is TT001, or a hydrochloride salt thereof. [Invention B1] The compound 4-[5-[(rac)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine (TT00), or 4-[5-[ (1R)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine, (TT001) and / or 4-[5-[(1S)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine (TT002), or a pharma- ceutically acceptable salt, solvate, isotope, or mixture thereof. [Invention B2] Compounds TT00, TT001 and / or TT002, or pharma- ceutically acceptable salts, solvates, isotopes or mixtures thereof, for use according to invention B1, wherein said dog, cat, horse or pig is under surgical conditions. [Invention B3] Compounds TT00, TT001 and / or TT002, or pharma- ceutically acceptable salts, solvates, isotopes or mixtures thereof, for use according to invention B1 or B2, wherein said dog, cat, horse or pig is treated with one or more muscle relaxants. [Invention B4] Compounds TT00, TT001 and / or TT002, or pharma- ceutically acceptable salts, solvates, isotopes or mixtures thereof, for use according to invention B2 or B3, wherein said compounds are administered preoperatively. [Invention B5] Compound TT00, TT001 and / or TT002, or a pharma- ceutically acceptable salt, solvate, isotope or mixture thereof, for use according to invention B2 or B3, wherein said compound is administered after said surgery. [Invention B6] Compounds TT00, TT001 and / or TT002, or pharma- ceutically acceptable salts, solvates, isotopes or mixtures thereof, for use according to any one of inventions B1 to B5 in combination with the prophylaxis and / or treatment of ulcers, renal and / or vascular disorders. [Invention B7] Compound TT00, TT001 and / or TT002, or a pharma- ceutically acceptable salt, solvate, isotope or mixture thereof, for use according to any one of inventions B1 to B5 in combination with the prophylaxis and / or treatment of wound healing and / or anorexia. [Invention B8] Compounds TT00, TT001 and / or TT002, or pharma- ceutically acceptable salts, solvates, isotopes or mixtures thereof, for use according to any one of inventions B1 to B5 in combination with the prophylaxis and / or treatment of gastroesophageal reflux by surgery. [Invention B9] Compound TT00, TT001 and / or TT002, or a pharma- ceutically acceptable salt, solvate, isotope or mixture thereof, for use according to any one of Inventions B1 to B5 in combination with anxiety. [Invention B10] Compounds TT00, TT001 and / or TT002, or pharma- ceutically acceptable salts, solvates, isotopes or mixtures thereof, for use according to any one of inventions B1 to B5 in combination with the prophylaxis and / or treatment of surgical gastroesophageal reflux and anxiety. [Invention B11] A pharmaceutical composition comprising compounds TT00, TT001 and / or TT002, or pharma- ceutically acceptable salts, solvates, isotopes or mixtures thereof, in combination with a pharma- ceutically acceptable adjuvant, diluent or carrier, for use in the prophylaxis and / or treatment of stress, in combination with one or more disorders including gastroesophageal reflux due to surgery, anxiety, ulcers, renal and vascular disorders, wound healing and anorexia. [Invention B12] A pharmaceutical composition according to Invention B11 comprising (i) compound TT00, TT001 and / or TT002, or a pharma- ceutically acceptable salt, solvate or isotope thereof or a mixture thereof, (ii) a further therapeutic agent, or a pharma- ceutically acceptable salt or solvate thereof, and (iii) a pharma- ceutically acceptable excipient, carrier or diluent. [Invention B13] A pharmaceutical composition according to Invention B11 comprising (i) compound TT00, TT001 and / or TT002, or a pharma- ceutically acceptable salt, solvate or isotope thereof or a mixture thereof, and a pharma- ceutically acceptable excipient, carrier or diluent, (ii) a further therapeutic agent, or a pharma- ceutically acceptable salt or solvate thereof, and a pharma- ceutically acceptable excipient, carrier or diluent. [Invention B14] A pharmaceutical composition according to inventions B11 to B13, wherein said further therapeutic agent is an NSAID selected from the group comprising butylpyrrolidine, oxicams, propionic acid derivatives, fenamates, coxibs, and other non-steroidal anti-inflammatory drugs. [Invention B15] A pharmaceutical composition according to Inventions B11 to B13, wherein said further therapeutic agent is an opiate selected from the group comprising tramadol or tapentadol. [Invention B16] A pharmaceutical composition according to any one of Inventions B11 to B13, wherein said further therapeutic agent is an antirheumatic drug. [Invention B17] Compounds TT00, TT001 and / or TT002 according to any one of Inventions B1 to B10, or pharma- ceutically acceptable salts, solvates, isotopes or mixtures thereof, or a pharmaceutical composition according to any one of Inventions B11 to B16, wherein compounds TT00, TT001 and / or TT002 are administered to dogs, cats, horses or pigs at a dose of 0.1 to 5.0 mg / kg. [Invention B18] Compound TT00, TT001 and / or TT002 according to any one of Inventions B1 to B10, B17, or a pharma- ceutically acceptable salt, solvate, isotope or mixture thereof, or a pharmaceutical composition according to any one of Inventions B11 to B17, wherein said compound is TT001, or a hydrochloride salt thereof. [Invention B19] Compound TT00, TT001 and / or TT002 according to any one of inventions B1 to B10, B17, B18, or a pharma- ceutically acceptable salt, solvate, isotope or mixture thereof, or a pharmaceutical composition according to any one of inventions B11 to B18, for use in a dog. Effect of the Invention

[0044] See CG Abdallah, et al., Chronic Stress (Thousand Oaks). 2017 Feb;1, there is no reason to assume that a substance that acts on pain can be used as an indicator of stress. Furthermore, the efficacy of TT001 for use in pain treatment has not been shown. TT001 has been shown to be ineffective in treating depression and anxiety. However, new results show an unexpected effect of the substance in treating stress / overwork. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0045] In another embodiment, the compound is the hydrochloride salt of TT001. In a further embodiment, the compound is the sulfate salt of TT001. In one embodiment, the mammal is a dog, cat, horse, or pig.

[0046] In normal surgery / surgical situations, anesthetics such as acepromazine, morphine and propofol are used. Anesthetics such as acepromazine have muscle relaxant properties that affect the lower esophageal sphincter (LES), causing more reflux episodes during anesthesia. It may therefore be advantageous to administer compounds TT00, TT001 and / or TT002 under surgical conditions. In one aspect, compounds TT00, TT001 and / or TT002 as defined above are for use in the prevention and / or treatment of fatigue in mammals under surgical conditions. In another aspect, compounds TT00, TT001 and / or TT002 as defined above are for use in the prevention and / or treatment of fatigue in mammals treated with one or more muscle relaxants. In a further aspect, compounds TT00, TT001 and / or TT002 as defined above are for use in the prevention and / or treatment of fatigue in mammals treated with one or more muscle relaxants under surgical conditions. In one embodiment, the compound as defined above is for use in the prevention of fatigue in a mammal. The compound may be administered before, during and / or after surgery on the mammal. In one embodiment, the compound is administered before surgery. It is advantageous if the mammal is relaxed / unstressed before surgery. The reduced stress makes the animal easier to handle before surgery. Compound TT001 may also reduce reflux, so the effect on gastroesophageal reflux is reduced. In another embodiment, the compound is administered after surgery. It is advantageous if the mammal is relaxed after surgery. It is believed that the reduction in stress levels in the mammal after surgery reduces stress-related complications that may occur due to post-operative stress, such as gastric disorders, brain damage, kidney and / or vascular disorders, wound healing and / or loss of appetite.

[0047] In one embodiment, the compounds TT00, TT001 and / or TT002 as defined above are for use in the prevention and / or treatment of fatigue, in combination with the prevention and / or treatment of ulcers, kidney and / or vascular disorders. In one embodiment, the compounds TT00, TT001 and / or TT002 as defined above are for use in the prevention and / or treatment of fatigue, in combination with the prevention and / or treatment of ulcers. In one embodiment, the compounds TT00, TT001 and / or TT002 as defined above are for use in the prevention and / or treatment of fatigue, in combination with the prevention and / or treatment of kidney and / or vascular disorders. In another embodiment, the mammal is under surgical conditions and / or is treated with one or more muscle relaxants. In one embodiment, the compounds as defined above are for use in the prevention of fatigue in a mammal. As mentioned above, disorders such as ulcers, kidney and / or vascular disorders may occur in stressed mammals or in association with surgery. It is believed that mGluR antagonists such as compounds TT00, TT001 and / or TT002 may prevent the development of and / or treat these disorders, particularly in stressed mammals.

[0048] In one embodiment, the compounds TT00, TT001 and / or TT002 as defined above are for use in the prevention and / or treatment of fatigue, in combination with the prevention and / or treatment of (poor) wound healing. In one embodiment, the compounds TT00, TT001 and / or TT002 as defined above are for use in the prevention and / or treatment of fatigue, in combination with the prevention and / or treatment of anorexia. In another embodiment, the mammal is under surgical conditions and / or is treated with one or more muscle relaxants. In one embodiment, the compounds as defined above are for use in the prevention of fatigue in a mammal. As mentioned above, disorders such as poor wound healing and / or anorexia can occur in stressed mammals or in association with surgery. Two important parts of recovery after surgery / surgical procedures are that the wound heals quickly and without complications and that the mammal starts eating and drinking. These two conditions of wound healing and eating are controlled by the stress level of the mammal. It is believed that mGluR antagonists such as compounds TT00, TT001 and / or TT002 may prevent the development of and / or treat these disorders, particularly in stressed mammals.

[0049] In one embodiment, the compounds TT00, TT001 and / or TT002 as defined above are for use in the prevention and / or treatment of fatigue, in combination with the prevention and / or treatment of surgical gastroesophageal reflux. In another embodiment, the mammal is under surgical conditions and / or is treated with one or more muscle relaxants. The reflux can be preoperative gastroesophageal reflux, intraoperative gastroesophageal reflux and / or postoperative gastroesophageal reflux. In one embodiment, the compounds as defined above are for use in the prevention of fatigue in a mammal. The compounds can have a positive effect on gastroesophageal reflux, which can be increased in stressed mammals, especially under surgical conditions. It is therefore believed that mGluR antagonists such as compounds TT00, TT001 and / or TT002 can prevent the occurrence of surgical gastroesophageal reflux and / or treat surgical gastroesophageal reflux in mammals, especially stressed mammals.

[0050] In one embodiment, the compounds TT00, TT001 and / or TT002 as defined above are for use in the prevention and / or treatment of fatigue, in combination with anxiety. In another embodiment, the mammal is under surgical conditions and / or is treated with one or more muscle relaxants. Compound TT001 has been shown to be ineffective in the treatment of anxiety, but has been found to be effective in the prevention and / or treatment of fatigue / stress. In one embodiment, the compounds as defined above are for use in the prevention of fatigue in mammals. It is therefore believed that mGluR antagonists such as compounds TT00, TT001 and / or TT002 can prevent the occurrence of anxiety and / or treat anxiety in mammals, particularly stressed mammals.

[0051] In one embodiment, the compounds TT00, TT001 and / or TT002 as defined above are for use in the prevention and / or treatment of fatigue, in combination with the prevention and / or treatment of gastroesophageal reflux and anxiety caused by surgery. In another embodiment, the mammal is under surgical conditions and / or is treated with one or more muscle relaxants. In one embodiment, the compounds as defined above are for use in the prevention of fatigue in a mammal. It is believed that mGluR antagonists such as compounds TT00, TT001 and / or TT002 can also prevent the occurrence of gastroesophageal reflux and anxiety and / or treat gastroesophageal reflux and anxiety in a mammal.

[0052] In some aspects, the mammal is a dog, cat, horse or pig in any of the above uses or combination of uses. In one aspect, the mammal is a dog. In another aspect, the mammal is a cat or horse.

[0053] In some embodiments, the compound is TT001, or a hydrochloride or sulfate salt thereof.

[0054] In some embodiments, the prevention and / or treatment of one or more disorders selected from surgical gastroesophageal reflux, anxiety, ulcers, renal and vascular disorders, wound healing and / or anorexia is performed in a stressed mammal, i.e., in a mammal that has elevated levels of cortisol release and hippocampal activation.

[0055] In some embodiments, prevention and / or treatment of pain is denied. In some embodiments, prevention and / or treatment of depression is denied.

[0056] Compounds TT00, TT001 and / or TT002 show little side effects at intended doses. They do not lose efficacy over longer administration periods. The compounds defined above are believed to have a low potential for side effects compared to conventional drugs currently used in mammals, such as NSAIDs. The compounds of the present invention are believed to have reduced gastrointestinal and renal toxicity.

[0057] The present invention further relates to a pharmaceutical composition comprising compounds TT00, TT001 and / or TT002, or their pharma- ceutically acceptable salts, solvates, isotopes or mixtures, optionally in combination with a pharma- ceutically acceptable adjuvant, diluent or carrier, for use in the prophylaxis and / or treatment of fatigue, optionally in combination with one or more disorders selected from the group consisting of or consisting of surgical gastroesophageal reflux, anxiety, ulcers, renal and vascular disorders, wound healing and anorexia. In another embodiment, the mammal is under surgical conditions and / or is treated with one or more muscle relaxants. In one embodiment, the compound as defined above is for use in the prophylaxis of fatigue in a mammal. The reflux may be preoperative gastroesophageal reflux, intraoperative gastroesophageal reflux and / or postoperative gastroesophageal reflux.

[0058] The present invention also relates to a method for preparing a pharmaceutical composition as defined above, comprising mixing the compounds TT00, TT001 and / or TT002 with a pharma- ceutically acceptable adjuvant, diluent or carrier. In one embodiment, the compound is TT001, or its hydrochloride or sulfate salt.

[0059] The compounds TT00, TT001 and / or TT002 as defined above can be administered at a dose of 0.1-5.0 mg / kg, or 0.1-2.0 mg / kg, or 0.1-1.0 mg / kg per day. One embodiment relates to a dosing regimen in which the compounds TT00, TT001 and / or TT002 as defined above are administered to a mammal once per day or twice per day at a dose of 0.1-5.0 mg / kg. In one embodiment, the dosing regimen is the administration of the compounds TT00, TT001 and / or TT002 as defined above at a dose of 0.1-1.0 mg / kg once per day. In some embodiments, the compound is TT001, or a hydrochloride or sulfate salt thereof. In some embodiments, the compound is TT001 or a hydrochloride salt thereof.

[0060] The shortening of recovery time and prevention and / or treatment of associated pathologies as defined herein may be applied as a sole treatment or may include, in addition to the compound, a joint treatment with a conventional treatment useful for preventing and treating one or more of the disease conditions mentioned herein. Such a conventional treatment may include one or more of the following categories of drugs: NSAIDs and opiates.

[0061] Mao et al. J. Pain, 2011, vol 12, pp 157-166, disclose various combination drug therapies for the treatment of pain. Most of the treatments use an opiate in combination with another analgesic. mGluRs are not mentioned for use in the combination therapy at all.

[0062] Such conjoint treatment may be achieved by simultaneous, sequential or separate administration of the individual components of the treatment.Such combination products employ compounds TT00, TT001 and / or TT002 as defined above for use in any of the above disorders.

[0063] In one aspect, the present invention relates to a pharmaceutical composition comprising (i) compounds TT00, TT001 and / or TT002 or pharma- ceutically acceptable salts, solvates or isotopes or mixtures thereof, (ii) a further therapeutic agent or a pharma- ceutically acceptable salt or solvate thereof, (iii) a pharma- ceutically acceptable excipient, carrier or diluent, for use in the prevention and / or treatment of fatigue, optionally in combination with one or more disorders selected from the group consisting of or including surgical gastroesophageal reflux, anxiety, ulcers, renal and vascular disorders, wound healing and anorexia. In one aspect, the compound as defined above is for use in the prevention of fatigue in a mammal.

[0064] In another aspect, the present invention relates to a pharmaceutical composition comprising (i) the compounds TT00, TT001 and / or TT002, or a pharma- ceutically acceptable salt, solvate or isotope or mixture thereof, and a pharma- ceutically acceptable excipient, carrier or diluent, (ii) a further therapeutic agent, or a pharma- ceutically acceptable salt or solvate thereof, and a pharma- ceutically acceptable excipient, carrier or diluent, for use in the prevention and / or treatment of fatigue, optionally in combination with one or more disorders selected from the group consisting of or including surgical gastroesophageal reflux, anxiety, ulcers, renal and vascular disorders, wound healing and anorexia. In one aspect, the compound as defined above is for use in the prevention of fatigue in a mammal.

[0065] In another embodiment, the at least one additional therapeutic agent is selected from the group consisting of an NSAID and an opiate.

[0066] In one aspect, the additional therapeutic agent is an NSAID, such as butylpyrrolidine, oxicams, propionic acid derivatives, fenamates, coxibs and other nonsteroidal anti-inflammatory and anti-rheumatic drugs.

[0067] Examples of NSAIDs may include anti-inflammatory, anti-rheumatic and / or non-steroidal NSAIDs. NSAIDs may be selected from the group including or consisting of butylpyrazolidiners (e.g., phenylbutazone), or oxicams (e.g., meloxicam), or propioncilazibat (e.g., ketoprofen, vedaprofen, carprofen and tepoxalin), or fenameter (e.g., tolfenantula, meclofenamusula and flunixin), or coxibar (e.g., pormacoxib, firocoxib, robenacoxib, mavacoxib and cimicoxib), or other non-steroidal anti-inflammatory and anti-rheumatic drugs (e.g., glucosaminoglycan polysulfate, pentosan polysulfate and grapiprant).

[0068] In one aspect, the additional therapeutic agent is an opiate, such as tramadol or tapentadol.

[0069] In another embodiment, the at least one additional therapeutic agent is an anti-rheumatic agent.

[0070] In one aspect, the present invention relates to a pharmaceutical composition comprising (i) the compound TT001 or its hydrochloride or sulfate salts, (ii) at least one agent selected from the group consisting of butylpyrrolidine, oxicams, propionic acid derivatives, fenamic acids, coxibs, and other nonsteroidal anti-inflammatory drugs, and NSAIDs such as antirheumatic drugs, and opiates such as tramadol and tapentadol, for use in the prevention and / or treatment of fatigue, optionally in combination with one or more disorders selected from the group consisting of or including surgical gastroesophageal reflux, anxiety, ulcers, renal and vascular disorders, wound healing and anorexia, and (iii) a pharmaceutically acceptable excipient, carrier or diluent. In one aspect, the compound as defined above is for use in the prevention of fatigue in a mammal.

[0071] Such combination products use the compounds defined above within the dosage ranges described herein, as well as other pharma- ceutical active compounds within the approved dosage ranges and / or dosages set forth in the publication references thereto. In one embodiment, when compounds TT00, TT001 and / or TT002 defined above and an additional therapeutic agent are used in a combination composition, the dosage range is 75% or 50% by weight of the prescribed dosage.

[0072] The pharmaceutical composition comprising the compounds TT00, TT001 and / or TT002 as defined above, optionally together with further agents as defined above, may be administered intravenously, intramuscularly or orally. In one embodiment, the pharmaceutical composition is administered intravenously or intramuscularly. TT001 may be administered before or after surgery in conjunction with anesthesia protocols. In one embodiment, the compound may be administered intramuscularly.

[0073] In one aspect, the compounds TT00, TT001 and / or TT002, or pharma- ceutically acceptable salts or solvates, diastereomers, enantiomers, isotopes, prodrugs or metabolites or mixtures thereof, for use before-during and / or after a situation in which the mammal experiences stress or is treated with one or more muscle relaxants, such as surgery on the mammal, to reduce stress in the mammal. In one aspect, the compounds TT00, TT001 and / or TT002, or pharma-ceutically acceptable salts or solvates, diastereomers, enantiomers, isotopes, prodrugs or metabolites or mixtures thereof, for use in reducing the time for recovery after surgery in a mammal, which time is reduced by at least 1 hour compared to before-during and / or after surgery without the use of TT00, TT001 and / or TT002.

[0074] The present invention also relates to compounds TT00, TT001 and / or TT002 or their pharma- ceutically acceptable salts or solvates, diastereomers, enantiomers, isotopes, prodrugs or metabolites or mixtures thereof for use in the prophylaxis and / or treatment of gastroesophageal reflux associated with surgery in combination with anxiety and / or pain associated with surgery, i.e. gastroesophageal reflux associated with surgery in combination with anxiety associated with surgery, or gastroesophageal reflux associated with surgery in combination with anxiety and pain associated with surgery. The reflux may be pre-operative, intra-operative and / or post-operative gastroesophageal reflux.

[0075] The present invention also relates to compounds TT00, TT001 and / or TT002, or pharma- ceutically acceptable salts or solvates, diastereomers, enantiomers, isotopes, prodrugs or metabolites or mixtures thereof, for use in the prophylaxis and / or treatment of ulcers, renal and / or vascular disorders associated with situations in which a mammal is undergoing stress, such as surgery, or is being treated with one or more muscle relaxants.

[0076] The present invention relates to a method for treating, preventing or reducing the risk of fatigue in a mammal, optionally under surgical conditions and / or treated with one or more muscle relaxants, optionally in combination with one or more disorders selected from surgical gastroesophageal reflux, anxiety, ulcers, renal and vascular disorders, wound healing and / or anorexia, comprising administering to a mammal in need thereof, such as a dog, pig, cat or horse, a therapeutically effective amount of the compounds TT00, TT001 and / or TT002 as defined above.

[0077] The present invention relates to a method for treating, preventing or reducing the risk of stress or surgery-induced gastroesophageal reflux in a mammal, or surgery-induced gastroesophageal reflux combined with anxiety and / or pain associated with surgery, or combined with ulcers, renal and / or vascular disorders associated with a situation in which the mammal experiences stress or is treated with one or more muscle relaxants, such as surgery in a mammal, comprising administering a therapeutically effective amount of the compounds TT00, TT001 and / or TT002, or a pharma- ceutically acceptable salt or solvate, diastereomer, enantiomer, isotope, prodrug or metabolite, or mixtures thereof, to a mammal, such as a dog, a pig, a cat or a horse, in need thereof. In one embodiment, the compound is TT001, or a hydrochloride or sulfate salt thereof.

[0078] DETAILED DESCRIPTION OF VARIOUS EMBODIMENTS OF THE PRESENTINVENTION The definitions set forth in this application are intended to clarify terms used throughout this application. The term "herein" means the entire application.

[0079] As used herein, "restoration" means the restoration or restoration of normal health and function.

[0080] It is to be understood that the term "compounds TT00, TT001 and / or TT002" includes pharma- ceutically acceptable salts, solvates, diastereomers, enantiomers, isotopes, prodrugs or metabolites, or mixtures thereof, unless otherwise specified.

[0081] As used herein, "pharmaceutically acceptable salts" refers to the form of the disclosed compounds, in which the parent compound is modified by forming its acid or base salt. Examples of pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of basic residues such as amines, alkali or organic salts of acidic residues such as carboxylic acids, and the like. Pharmaceutically acceptable salts include, for example, conventional non-toxic salts or quaternary ammonium salts of the parent compound formed from non-toxic inorganic or organic acids. Such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric acid. Examples of salts are the hydrochlorides or sulfates, in particular 4-[5-[(1R)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine hydrochloride or 4-[5-[(1R)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine sulfate.

[0082] The pharma- ceutically acceptable salts of the present invention can be synthesized from parent compounds that contain a basic or acidic moiety by conventional chemical methods. In general, such salts can be prepared by reacting the free acid or free base forms of these compounds with a stoichiometric amount of an appropriate base or acid in water or an organic solvent, or in a mixture of the two, generally using non-aqueous media such as diethyl ether, ethyl acetate, ethanol, isopropanol, or acetonitrile.

[0083] Compounds TT00, TT001 and / or TT002, particularly TT001, can exist in particular geometric or stereoisomeric forms, and the present invention contemplates all such compounds as being within its scope, including tautomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, racemic mixtures thereof, and other mixtures thereof.

[0084] As used herein, the phrase "or a pharma- ceutically acceptable salt" includes hydrates and solvates thereof.

[0085] As used herein, "surgery" refers to coma and non-coma surgery, where the mammal is unconscious or conscious. The operation may be a surgical operation. As used herein, "under surgical conditions" refers to performing an operation on a mammal, and includes the period from pre-operation to post-operation, where the pre-operation period may be from 1 to 4 days, and the post-operation period may be from 1 to 21 days. Thus, the term includes the entire period during which the mammal experiences stress due to performing an operation on the mammal.

[0086] As used herein, "fatigue" or "stress" or "a situation in which a mammal experiences stress" refers to a clinical condition in a mammal in which a clinician diagnoses one or more symptoms of stress present in the mammal.

[0087] As used herein, "TLESR" means transient lower esophageal sphincter relaxation. During relaxation of the lower esophageal sphincter, fluid from the stomach can enter the esophagus. This event is called "reflux."

[0088] As used herein, "wound healing" refers to poor or impaired wound healing, ie, healing of a wound in a mammal taking longer than normal.

[0089] As used herein, "mammal" may include any mammal. For some disorders or combinations of disorders, "mammal" may include humans. In some aspects, "mammal" refers to dogs, pigs, cats, or horses, rabbits, guinea pigs, rats, birds, mice, and cows. In other aspects, "mammal" refers to dogs, pigs, cats, or horses.

[0090] Compounds TT00, TT001 and / or TT002, in particular TT001, as defined herein may be isotopically labeled (or "radiolabeled"), in which case one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number normally found in nature (i.e. naturally occurring). Examples of suitable isotopes that may be incorporated include: 2 H (also written as "D" for deuterium), 3 H (also written as "T" for tritium), 11 C. 13 C. 14 C. 13 N, 15 N, 15 O. 17 O. 18 O. 18 F, 35 S, 36 Cl, 82 Br, 75 Br, 76 Br, 77 Br, 123 I, 124 I, 125 I and 131 I. The radionuclide used will depend on the particular application of the radiolabeled derivative. For example, for in vitro receptor labeling and competition assays: 3 H or 14 Compounds incorporating C are often useful. For radioimaging applications, 11 C or 18 F is often useful. In some embodiments, the radionuclide is 3 H. In some embodiments, the radionuclide is 14 C. In some embodiments, the radionuclide is 11 C. In some embodiments, the radionuclide is 18 F. The present invention includes any isotope for use in diagnostics in mammals such as dogs, pigs, cats or horses.

[0091] Compounds TT00, TT001 and / or TT002, especially TT001, can be administered orally, parenterally, bucally, vaginally, rectally, by inhalation, insufflation, sublingually, intramuscularly, subcutaneously, topically, intranasally, intraperitoneally, intrathoracic, intravenous, epidural, intrathecal, intraventricular and intraarticular injection.

[0092] Optimal dosages and frequency of administration will depend on the particular condition being treated and its severity, the species, age, sex, size and weight, diet, and general physical condition of the particular mammal, other medications the mammal may be taking, the route of administration, the formulation, and a variety of other factors known to physicians and others of ordinary skill in the art.

[0093] The amount of compound TT00, TT001 and / or TT002, particularly TT001, administered will vary for the mammal being treated and will vary from about 0.01 ng / kg body weight to 10 mg / kg body weight, or 0.1 ng / kg to 1 mg / kg per day. For example, the dosage can be readily ascertained by one of ordinary skill in the art from this disclosure and the knowledge of one of ordinary skill in the art. Thus, one of ordinary skill in the art can readily determine the amount of compound and any additives, vehicles and / or carriers in the composition to be administered in the methods described herein.

[0094] Compounds TT00, TT001 and / or TT002 can be prepared as the free base or a pharma- ceutically acceptable salt or solvate thereof by the methods described in U.S. Pat. No. 7,476,684 or WO 2007 / 040982, which are incorporated herein by reference.

[0095] For preparing pharmaceutical compositions from compounds TT00, TT001 and / or TT002, especially TT001, inert pharma- ceutically acceptable carriers can be either solid or liquid. Solid form compositions include powders, tablets, dispersible granules, capsules, cachets and suppositories. A solid carrier can be one or more substances that can also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents, and can also be sealing materials.

[0096] Liquid compositions include ointments, creams, gels, and aqueous liquids, which may be formulated inside a transdermal patch.

[0097] The method for preparing the capsules comprises the following steps: a) mixing compound TT00, TT001 or TT002, in particular TT001, with additives such as calcium hydrogen, phosphate and hydroxypropylcellulose and stirring for a period of time; b) adding further additives such as mannitol and croscarmellose sodium; c) adding water and granulating the mixture; d) drying the resulting granules; e) milling the dried granules; f) adding further additives such as sodium stearyl fumarate; g) mixing the resulting mixture; h) filling the mixture into a capsule or pressing the mixture into a tablet.

[0098] Pharmaceutical Compositions ointment TT001 weight: 0.1~100mg Weight of propylene carbonate: 50 milligrams Weight of solid paraffin: 30 milligrams Weight of white beeswax: 35 milligrams Weight of liquid paraffin: 110 milligrams Weight of white soft paraffin: 774.7 milligrams

[0099] cream TT001 weight: 0.1~100mg Propylene glycol weight: 100 milligrams Weight of isopropyl myristate: 50 milligrams Cetostearyl alcohol weight: 52.5 mg Citric acid monohydrate (E330) weight: 0.5 milligrams Weight of disodium phosphate anhydrous: 0.6 milligrams Water Weight: Add enough to achieve a target weight of 30 or 100 grams Weight of liquid paraffin: 400 milligrams Weight of Macrogol Cetostearyl Ether: 7.5 mg Weight of disodium phosphate dodecahydrate (E339): 1.5 milligrams Weight of imidurea: 2 milligrams

[0100] Formulation method for preparation of TT001 for intravenous administration Dosage, 0.1-10 mg / ml The formulation method is applicable for formulation concentrations of 0.1 mg / mL to 10 mg / mL, which corresponds to 0.262 μmol / mL to 26.2 μmol / mL.

[0101] MW of TT001: 381.8g / mol TT001 dissolution is moderate and complete dissolution takes several hours.

[0102] Vehicle Preparation of 40% w / v HPβCD solution in water for injection Excipient Hydroxypropyl-β-cyclodextrin, Kleptose, Roquette (HPβCD) 400 mg (40% w / v) Water for injection 1mL (1.13g) Appearance transparent Density 1.13g / cm 3

[0103] formulation Preparation of 0.1-10mg / ml TT001 intravenous formulations TT001 parent form 0.1~10mg Vehicle (40% w / v HPβCD solution in water for injection) up to 1 mL (1.13 g) Appearance transparent Density 1.13g / cm 3 comment TT001 dissolution is moderate and complete dissolution takes several hours.

[0104] ointment Weight of active substance in TT001: 0.1-50 milligrams Weight of propylene carbonate: 50 milligrams Weight of solid paraffin: 30 milligrams Weight of white beeswax: 35 milligrams Weight of liquid paraffin: 110 milligrams Weight of white soft paraffin: 774.7 milligrams

[0105] cream TT001 weight: 0.1~100mg Propylene glycol weight: 100 milligrams Weight of isopropyl myristate: 50 milligrams Cetostearyl alcohol weight: 52.5 mg Citric acid monohydrate (E330) weight: 0.5 milligrams Weight of disodium phosphate anhydrous: 0.6 milligrams Water Weight: Add enough to achieve a target weight of 30 or 100 grams Weight of liquid paraffin: 400 milligrams Weight of Macrogol Cetostearyl Ether: 7.5 mg Weight of disodium phosphate dodecahydrate (E339): 1.5 milligrams Weight of imidurea: 2 milligrams

[0106] Capsules [Table 1A] EXAMPLES

[0107] Example 1 In cats or dogs undergoing elective castration or ovariohysterectomy, TT001 has a positive effect on the duration of the recovery period.

[0108] Cage behavioral scoring using a simple descriptive scale was used to study recovery after sterilization. Dogs in the first group were premedicated with intramuscular (im) acepromazine and pethidine, or in the second group TT001 was also added as a premedication.

[0109] Sedation was scored with the SDS (Simple Descriptive Scale) 20-40 min after premedication. Dogs were induced with propofol. Anesthesia was maintained with isoflurane in oxygen. Intraoperative analgesia was provided with morphine before surgery. At the end of surgery, group 1 received meloxicam and group 2 received no additional treatment.

[0110] SDS was scored at the end of the procedure and recovery.

[0111] Group 2 showed the following: The time to extubation was shortened. The time it took to lift his head was reduced after surgery. It took me less time to get out of bed after surgery. Time to spontaneous / spontaneous voiding after surgery was shorter. Less nausea. The time it took to start eating after surgery was reduced. Lower cortisol levels than commonly used anesthesia protocols.

[0112] Example 2 In cats or dogs undergoing elective castration or ovariohysterectomy, TT001 has a positive effect on the duration of the recovery period.

[0113] To study recovery after sterilization, cage behavior scoring using a simple descriptive scale was used. Dogs in the first group were premedicated with acepromazine and pethidine im and meloxicam orally, or in the second group TT001 was also added as a premedication.

[0114] Sedation was scored with the SDS (Simple Descriptive Scale) 20-40 min after premedication. Dogs were induced with propofol. Anesthesia was maintained with isoflurane in oxygen. Intraoperative analgesia was provided with morphine before surgery. At the end of surgery, group 1 continued to receive meloxicam and group 2 continued to receive TT001 and meloxicam. No further treatment was performed.

[0115] SDS was scored at the end of the procedure and recovery.

[0116] Group 2 showed the following: The time to extubation was shorter than in Group 1. The time it took to lift their head after surgery was shorter than in Group 1. The time it took to get out of bed after surgery was shorter than in Group 1. The time to spontaneous / spontaneous voiding after surgery was shorter than that in Group 1. Nausea was less than in Group 1. The time to start eating after surgery was shorter than in Group 1. Lower cortisol levels than Group 1; and Intensive care / PACU unit time was shorter than in Group 1.

[0117] In this study, TT001 showed no effect on LES pressure. There was also no significant effect on swallowing observed with TT001 in this study, although there was a numerical trend toward decreased swallowing at higher doses, which may be consistent with a CNS-mediated effect.

[0118] Example 3: Forced swim test TT001 has been used in the forced swim test. For protocol, see Can A., et al., The Mouse Forced Swim Test, J Vis Exp. 2012;(59):3638.

[0119] The results in Table 1 show that the test animals still survived for a significantly shorter period than the placebo group.

[0120] [Table 1B]

[0121] This study shows that TT001 reduces stress. Furthermore, none of the test animals had signs of gastric ulcers or any changes in the mucosa.

[0122] Example 4: Learned Helplessness Research Nomura S. et al., Studies on animal model of depression: review and perspective, Review, Yakubutsu Seishin Kodo, 1989 Dec;9(4):349-58.

[0123] TT001 was used in a learned helplessness test in rats, and the results are shown in Table 2.

[0124] [Table 2]

[0125] The results show that TT001 reduced stress and no gastric ulcer appeared, therefore TT001 has specific therapeutic effects on stress and gastric ulcer.

[0126] Example 5. Stress and Experiments - Ulcers Toxicity studies of TT001 in dogs were conducted using doses of 2, 6, 7 or 31 mg / kg for up to 52 weeks. Dogs were gavaged throughout the period and blood was collected throughout the period.

[0127] Balcome at al Contemporary Topics 2004 by the American Association for Laboratory Animal Science.Vol43.No.6 / November 2004 showed that gavage and regular blood sampling bring a lot of stress to the animals and that increased cortisol levels are normal under these circumstances. Furthermore, the animals are isolated and live in small areas which further increases stress.

[0128] After 52 weeks, none of the animals showed signs of gastric ulcers, despite the fact that the environment and handling during the 52 weeks had caused stress. The results indicate that TT001 is an agent that reduces stress and therefore the risk of gastric ulcers.

Claims

1. A pharmaceutical composition for use in the prevention and / or treatment of stress in combination with one or more disorders selected from the group consisting of surgical gastroesophageal reflux, anxiety, gastric ulcers, esophageal ulcers, renal and vascular disorders, wound healing and anorexia in dogs, cats, horses or pigs, comprising the compound 4-[5-[(rac)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine (TT00), or 4-[ A pharmaceutical composition comprising 5-[(1R)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine, (TT001) and / or 4-[5-[(1S)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine (TT002), or a pharma- ceutically acceptable salt, solvate, isotope, or mixture thereof.

2. 2. The pharmaceutical composition of claim 1, wherein the dog, cat, horse or pig is under surgical conditions.

3. 3. The pharmaceutical composition of claim 1 or 2, wherein the dog, cat, horse or pig is treated with one or more muscle relaxants.

4. The method of claim 2 or 3, wherein the compound is administered preoperatively.

5. The method of claim 2 or 3, wherein the compound is administered after the surgery.

6. A pharmaceutical composition described in any one of claims 1 to 5 in combination with the prevention and / or treatment of gastric ulcer, esophageal ulcer, renal and / or vascular disorders.

7. 6. A pharmaceutical composition according to any one of claims 1 to 5 in combination with the prevention and / or treatment of wound healing and / or anorexia.

8. 6. A pharmaceutical composition according to any one of claims 1 to 5 in combination with the prevention and / or treatment of gastroesophageal reflux through surgery.

9. A pharmaceutical composition according to any one of claims 1 to 5 in combination with the prevention and / or treatment of anxiety disorders.

10. 6. A pharmaceutical composition according to any one of claims 1 to 5 in combination with the prevention and / or treatment of gastroesophageal reflux and anxiety due to surgery.

11. 2. The compound 4-[5-[(rac)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine (TT00), ... in combination with a pharma- ceutically acceptable adjuvant, diluent or carrier, for use in the prophylaxis and / or treatment of stress, in combination with one or more disorders including gastroesophageal reflux due to surgery, anxiety, gastric ulcer, esophageal ulcer, renal and vascular disorders, wound healing and anorexia. A pharmaceutical composition comprising [(1R)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine, (TT001) and / or 4-[5-[(1S)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine (TT002), or a pharma- ceutically acceptable salt, solvate, isotope or mixture thereof.

12. 12. The pharmaceutical composition of claim 11, comprising: (i) compound TT00, TT001 and / or TT002, or a pharma- ceutically acceptable salt, solvate or isotope thereof or a mixture thereof; (ii) a further therapeutic agent, or a pharma- ceutically acceptable salt or solvate thereof; and (iii) a pharma- ceutically acceptable excipient, carrier or diluent.

13. 12. The pharmaceutical composition of claim 11 comprising (i) compound TT00, TT001 and / or TT002, or a pharma- ceutically acceptable salt, solvate or isotope thereof, or a mixture thereof, and a pharma- ceutically acceptable excipient, carrier or diluent, (ii) a further therapeutic agent, or a pharma- ceutically acceptable salt or solvate thereof, and a pharma- ceutically acceptable excipient, carrier or diluent.

14. 14. The pharmaceutical composition of claim 12 or 13, wherein the further therapeutic agent is an NSAID selected from the group including butylpyrrolidine, oxicams, propionic acid, fenamic acids, coxibs, and other nonsteroidal anti-inflammatory drugs.

15. 14. The pharmaceutical composition of claim 12 or 13, wherein the further therapeutic agent is an opiate selected from the group comprising tramadol or tapentadol.

16. 14. The pharmaceutical composition of claim 12 or 13, wherein the further therapeutic agent is an anti-rheumatic drug.

17. 17. The pharmaceutical composition according to any one of claims 1 to 16, wherein the compounds TT00, TT001 and / or TT002 are administered to dogs, cats, horses or pigs at a dose of 0.1 to 5.0 mg / kg.

18. 18. The pharmaceutical composition of any one of claims 1 to 17, wherein the compound is TT001, or a hydrochloride salt thereof.

19. 20. A pharmaceutical composition according to any one of claims 1 to 18 for use in dogs.

Citation Information

Patent Citations

  • Novel compounds for the treatment of neurological, psychiatric or pain disorders

    JP2009510064A